EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The clinical application of metagenomic next-generation sequencing for invasive pulmonary aspergillosis in neutropenic patients: a multicenter retrospective study in the ICU

Jing Tang, Jiahao Deng, Kai Guo, Yong Song, Junjie Zhao, Xiaojing Zhang, Youqin Yan, Lingmin Yuan, Yi Zhang, Canhu Qiu, Jian Luo, Honglong Fang und 1 weitere

Frontiers in Cellular and Infection Microbiology · 03.08.2026 · 16

DOI: 10.3389/fcimb.2026.1878097 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 03.08.2026. Verfasst von Jing Tang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Jin Hua Graduate Joint Training Base, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Invasive Pulmonary Aspergillosis, Neutropenia, Metagenomics, High-Throughput Nucleotide Sequencing. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early initiation of targeted antifungal therapy is critical for improving outcomes in neutropenic patients with invasive pulmonary aspergillosis (IPA) in the intensive care unit (ICU). Although metagenomic next-generation sequencing (mNGS) is valuable for pathogen detection, its clinical value in IPA patients with neutropenia remains unclear.

Methods

This multicenter retrospective study included patients clinically diagnosed with invasive pulmonary aspergillosis (IPA). All patients underwent both conventional microbiological tests (CMTs) and metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid (BALF). Based on neutrophil status, patients were stratified into neutropenic and non-neutropenic groups and further divided into mNGS-guided and CMT-guided groups according to the antifungal treatment strategy. Results mNGS demonstrated higher pathogen detection rate than conventional microbiological tests (CMTs) in both neutropenic and non-neutropenic patients with invasive pulmonary aspergillosis (IPA). It also identified a broader pathogen spectrum and a higher proportion of mixed infections. Overall, IPA patients in the mNGS-guided group had lower 28-day mortality compared with the CMT-guided group (23.17% vs. 43.75%, P = 0.04). Multivariate analysis indicated that mNGS-guided therapy was associated with reduced 28-day mortality (adjusted OR = 0.329, 95% CI: 0.111–0.974, P = 0.045). A significant interaction between treatment strategy and neutrophil status was observed (adjusted P = 0.002). In subgroup analysis, the survival benefit of mNGS-guided therapy was mainly observed in neutropenic IPA patients, who achieved higher rates of appropriate antifungal therapy and lower mortality, whereas no significant intergroup difference was found among non-neutropenic IPA patients. Conclusion mNGS-guided antifungal therapy significantly reduced 28-day mortality in neutropenic IPA patients, whereas no clear effect was observed in non-neutropenic patients. These findings highlight the potential clinical value of mNGS in guiding antifungal therapy in neutropenic IPA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Invasive Pulmonary AspergillosisNeutropeniaMetagenomicsHigh-Throughput Nucleotide SequencingHumansRetrospective StudiesFemaleIntensive Care UnitsMaleAntifungal AgentsMiddle AgedBronchoalveolar Lavage FluidAgedAdultTreatment Outcome

Stichwörter der Autor:innen

antifungal therapyinvasive pulmonary aspergillosismetagenomic next-generation sequencingneutropeniatreatment outcome

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Jin Hua Graduate Joint Training Base, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Emergency and Critical Care Center, Department of Emergency Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.
  • WillingMed Technology Beijing Co., Ltd, Beijing, China.
  • Department of Critical Care Medicine, People's Hospital of Changshan County, Quzhou, Zhejiang, China.
  • Department of Critical Care Medicine, Longyou County People's Hospital, Quzhou, Zhejiang, China.
  • Department of Critical Care Medicine, Quzhou Kecheng People's Hospital, Quzhou, Zhejiang, China.

Zitieren

APA

Tang, J., Deng, J., Guo, K., Song, Y., Zhao, J., Zhang, X., Yan, Y., Yuan, L., Zhang, Y., Qiu, C., Luo, J., Fang, H., & Zhuge, J. (2026). The clinical application of metagenomic next-generation sequencing for invasive pulmonary aspergillosis in neutropenic patients: a multicenter retrospective study in the ICU. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1878097

Vancouver

Tang J, Deng J, Guo K, Song Y, Zhao J, Zhang X, et al. The clinical application of metagenomic next-generation sequencing for invasive pulmonary aspergillosis in neutropenic patients: a multicenter retrospective study in the ICU. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1878097

BibTeX
@article{Tang2026,
  author = {Tang, Jing and Deng, Jiahao and Guo, Kai and Song, Yong and Zhao, Junjie and Zhang, Xiaojing and Yan, Youqin and Yuan, Lingmin and Zhang, Yi and Qiu, Canhu and Luo, Jian and Fang, Honglong and Zhuge, Jiancheng},
  title = {The clinical application of metagenomic next-generation sequencing for invasive pulmonary aspergillosis in neutropenic patients: a multicenter retrospective study in the ICU},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1878097}
}
Kostenlos starten →